These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66 related articles for article (PubMed ID: 33827)
21. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors. Oger S; Méhats C; Barnette MS; Ferré F; Cabrol D; Leroy MJ Biol Reprod; 2004 Feb; 70(2):458-64. PubMed ID: 14561639 [TBL] [Abstract][Full Text] [Related]
22. Lack of cyclic AMP-specific phosphodiesterase 4 activation during naloxone-precipitated morphine withdrawal in rats. Kimura M; Tokumura M; Itoh T; Inoue O; Abe K Neurosci Lett; 2006 Aug; 404(1-2):107-11. PubMed ID: 16753260 [TBL] [Abstract][Full Text] [Related]
23. Roflumilast for the treatment of chronic obstructive pulmonary disease. Antoniu SA Curr Opin Investig Drugs; 2006 May; 7(5):412-7. PubMed ID: 16729716 [TBL] [Abstract][Full Text] [Related]
24. Opiates, cyclic nucleotides, and xanthines. Collier HO; Francis DL; Roy AC Adv Biochem Psychopharmacol; 1976; 15():337-45. PubMed ID: 192053 [TBL] [Abstract][Full Text] [Related]
25. Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats. Chapman RW; House A; Jones H; Richard J; Celly C; Prelusky D; Ting P; Hunter JC; Lamca J; Phillips JE Eur J Pharmacol; 2007 Oct; 571(2-3):215-21. PubMed ID: 17610865 [TBL] [Abstract][Full Text] [Related]
26. Characteristics of the cyclic nucleotide phosphodiesterases in a transplantable pheochromocytoma and adrenal medulla of the rat. Levin RM; Weiss B Cancer Res; 1978 Apr; 38(4):915-20. PubMed ID: 205349 [No Abstract] [Full Text] [Related]
27. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma. Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605 [TBL] [Abstract][Full Text] [Related]
28. Effects of fenspiride on human bronchial cyclic nucleotide phosphodiesterase isoenzymes: functional and biochemical study. Cortijo J; Naline E; Ortiz JL; Berto L; Girard V; Malbezin M; Advenier C; Morcillo EJ Eur J Pharmacol; 1998 Jan; 341(1):79-86. PubMed ID: 9489859 [TBL] [Abstract][Full Text] [Related]
29. [The anti-allergic activity and mechanism of action of gamma-carboline derivatives]. Kiseleva EE; Zakharevskiĭ AS; Nikiforova IN Farmakol Toksikol; 1990; 53(3):22-4. PubMed ID: 1696908 [TBL] [Abstract][Full Text] [Related]
30. [Adenosine cyclic monophosphate level, adenyl cyclase activity, 3,5'-cyclic AMP phosphodiesterase and protein kinases in rat brain in experimental carbon monoxide poisoning]. Sikorska M Neuropatol Pol; 1980; 18(2):203-17. PubMed ID: 6251408 [No Abstract] [Full Text] [Related]
31. Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy. Verhoest PR; Proulx-Lafrance C; Corman M; Chenard L; Helal CJ; Hou X; Kleiman R; Liu S; Marr E; Menniti FS; Schmidt CJ; Vanase-Frawley M; Schmidt AW; Williams RD; Nelson FR; Fonseca KR; Liras S J Med Chem; 2009 Dec; 52(24):7946-9. PubMed ID: 19919087 [TBL] [Abstract][Full Text] [Related]
33. [Effect of thyroxine on the contents of cyclic AMP and on the activity of cyclic AMP phosphodiesterase in hepatocytes of the rat]. Leoni S; Spagnuolo S Boll Soc Ital Biol Sper; 1975 Dec; 51(23):1874-8. PubMed ID: 182190 [No Abstract] [Full Text] [Related]
34. General properties of multiple molecular forms of cyclic nucleotide phosphodiesterase in the nervous system. Strada SJ; Martin MW; Thompson WJ Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 16():13-29. PubMed ID: 6326518 [No Abstract] [Full Text] [Related]
35. Membraneous and cytosolic cyclic-nucleotide phosphodiesterases in beef aorta: substrate specificity, endogenous inhibition and activation [proceedings]. Ilien B; Morel A; Stierle A; Landry Y Arch Int Physiol Biochim; 1978 Oct; 86(4):865-7. PubMed ID: 84582 [No Abstract] [Full Text] [Related]
36. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633. Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523 [TBL] [Abstract][Full Text] [Related]
37. Phosphodiesterase 4 inhibitors: antiinflammatory therapy for chronic obstructive pulmonary disease at last? Kerstjens HA; Timens W Am J Respir Crit Care Med; 2003 Oct; 168(8):914-5. PubMed ID: 14555456 [No Abstract] [Full Text] [Related]
38. Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors. Crespo MI; Pagès L; Vega A; Segarra V; López M; Doménech T; Miralpeix M; Beleta J; Ryder H; Palacios JM J Med Chem; 1998 Oct; 41(21):4021-35. PubMed ID: 9767640 [TBL] [Abstract][Full Text] [Related]
39. [Modulation of reactivity of cyclic adenosine monophosphate phosphodiesterase under the effect of pyridinecarboxylic acid derivatives and Pt(IV) metal complexes on their basis]. Tat'ianenko LV; Bogdanov GN; Dobrokhotova OV; Fadeev MA; Fedorov BS Biomed Khim; 2006; 52(2):174-9. PubMed ID: 16805389 [TBL] [Abstract][Full Text] [Related]
40. The effects of traxanox sodium of cyclic AMP phosphodiesterase and the concentration of cyclic AMP in the plasma of rats. Ikegami K; Hirano S; Hasegawa G Chem Pharm Bull (Tokyo); 1983 Feb; 31(2):752-5. PubMed ID: 6309423 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]